US PTO denies Apotex bid for re-exam of Plavix patent
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb and Sanofi-Aventis have achieved another legal victory, after the US Patent and Trademark Office (PTO) denied generic firm Apotex's second request for re-examination of the compound patent for the blockbuster antiplatelet drug, Plavix (clopidogrel).